Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Viridian Therapeutics, Inc.
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
July 25, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
June 11, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
May 31, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
May 10, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
April 29, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
December 18, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
November 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
November 03, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
October 30, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
October 26, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
September 25, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
September 07, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Tickers
VRDN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.